Spartanburg Regional Healthcare System (SRHS) in South Carolina, US, has implemented the 2bPrecise enterprise platform for precision care and genomics.
This multi-year collaboration has led to the integration of 2bPrecise-driven applications across SRHS's extensive network, which encompasses six hospitals, over 150 offices, and a base of 700 physicians.
The 2bPrecise platform is designed to enhance the delivery of precision care solutions within electronic health record (EHR) workflows.
SRHS has adopted several applications from 2bPrecise to meet its genomics and precision care goals, particularly in oncology.
These encompass the 2bPrecise Diagnostic Workflow, which orchestrates discrete outcomes from multiple specialist laboratory services, and the 2bPrecise Oncology Workflow that provides evaluation capabilities for both somatic and inherited data, potential therapies, and clinical trials.
Additionally, the 2bPrecise Precision Timeline application provides a patented longitudinal framework that enables providers to assess a patient's past medical data, interventions, and therapeutic procedures.
The platform also supports pharmacogenomics and tailored medication management programmes at the population scale, facilitated by YouScript.
SRHS executive vice-president and chief operating officer Charles Morrow said: "This partnership with 2bPrecise reinforces SRHS's commitment to precision medicine and healthcare innovation leadership, making it easier than ever for providers to access, assess, and incorporate precision care solutions into their existing workflows.”
The 2bPrecise Enterprise system allows healthcare organisations to manage and leverage discrete diagnostic results, genomic insights, and multi-source system data.
It is a vendor and EHR-agnostic platform, facilitating swift benefits for the broad implementation and growth of precision medicine offerings.
2bPrecise chief strategy officer Joe Spinelli said: "The modular and scalable framework of 2bPrecise Enterprise is a perfect match with SHRS's ambition and vision to systematically unlock the true power of personalised medicine.
“We look forward to continuing to expand the scope of applications and impact from these programmes."
